The purpose of this study is to evaluate the effectiveness of 2 doses or 3 doses of GSK's
licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's
investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy
adolescents and young adults. The immunogenicity and safety will also be evaluated in the
As per the feedback from Center for Biologics Evaluation and Research (CBER) the scope of
this post-marketing commitment study has been extended to demonstrate the effectiveness,
immunogenicity and safety of GSK's investigational combined meningococcal ABCWY vaccine along
with the rMenB+OMV NZ vaccine. Note that the rMenB+OMV and MenACWY vaccines provided to
MenB_0_2_6, MenB_0_6 group and MenACWY group respectively at day 211 are only as part of
standard care of treatment and to maintain blinding. These vaccination schedules are not
considered for any endpoint evaluations.
rMenB+OMV NZ vaccine,
Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY),
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.